Mountain View, Calif.-based Fogarty Institute said the companies are each developing treatments for women’s health. The not-for-profit institute, named for medical device legend Dr. Tom Fogarty, incubates early-stage medtech ventures, providing intellectual, physical and financial resources.
“Women’s health has historically been underdeveloped and underfunded in terms of medical innovation, yet it offers an opportunity to revolutionize patient care globally,” institute president & CEO Ann Fyfe said in prepared remarks. “We are excited to not only increase the number of medical technologies aimed at helping women, but also delighted to support more women leaders in this industry.
“We are also proud of our success rate in launching medical device companies and our ability to help them obtain Series A funding – a critical milestone startups must achieve to commercialize their technologies. Six Fogarty Institute companies have now achieved this turning point, making their vital technologies one step closer to benefitting patients,” Fyfe added.
Igantia is developing a 1st-of-its-kind medical device/digital health technology for hot flashes, the Fogarty Institute said. Marz Medical and founder Dr. Joshua Korman of Stanford University are developing the Blossom tissue expansion technology aimed at reducing pain and recovery time for patients undergoing breast or burn reconstruction surgery. The device won 510(k) clearance from the FDA in July 2014.
The institute said Madorra is developing the 1st, non-hormonal, medical device treatment for vaginal dryness and atrophy.
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.